AU2002319296A1 - Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes - Google Patents

Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes

Info

Publication number
AU2002319296A1
AU2002319296A1 AU2002319296A AU2002319296A AU2002319296A1 AU 2002319296 A1 AU2002319296 A1 AU 2002319296A1 AU 2002319296 A AU2002319296 A AU 2002319296A AU 2002319296 A AU2002319296 A AU 2002319296A AU 2002319296 A1 AU2002319296 A1 AU 2002319296A1
Authority
AU
Australia
Prior art keywords
alkoxyphenyl
treatment
diseases associated
regulated processes
substituted imidazotriazinones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002319296A
Other versions
AU2002319296B2 (en
Inventor
Tiemo-Joerg Bandel
Wolfgang Barth
Erwin Bischoff
Helmut Haning
Ulrich Niewohner
Afssaneh Rahbar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10135815A external-priority patent/DE10135815A1/en
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of AU2002319296A1 publication Critical patent/AU2002319296A1/en
Application granted granted Critical
Publication of AU2002319296B2 publication Critical patent/AU2002319296B2/en
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Request for Assignment Assignors: BAYER HEALTHCARE AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002319296A 2001-07-23 2002-07-17 Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cGMP regulated processes Ceased AU2002319296B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10135815.6 2001-07-23
DE10135815A DE10135815A1 (en) 2001-07-23 2001-07-23 Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
PCT/EP2002/007959 WO2003011262A2 (en) 2001-07-23 2002-07-17 Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cgmp regulated processes

Publications (2)

Publication Number Publication Date
AU2002319296A1 true AU2002319296A1 (en) 2003-05-29
AU2002319296B2 AU2002319296B2 (en) 2007-08-30

Family

ID=7692784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002319296A Ceased AU2002319296B2 (en) 2001-07-23 2002-07-17 Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cGMP regulated processes

Country Status (28)

Country Link
US (3) US6930108B2 (en)
EP (2) EP1733728A3 (en)
JP (1) JP2005504751A (en)
KR (1) KR20040032865A (en)
CN (1) CN1649593A (en)
AT (1) ATE442144T1 (en)
AU (1) AU2002319296B2 (en)
BG (1) BG108533A (en)
BR (1) BR0211359A (en)
CA (1) CA2454414A1 (en)
CO (1) CO5560536A2 (en)
CZ (1) CZ2004128A3 (en)
DE (2) DE10135815A1 (en)
EC (1) ECSP044956A (en)
EE (1) EE200400056A (en)
ES (1) ES2330418T3 (en)
HR (1) HRP20040065A2 (en)
HU (1) HUP0500734A3 (en)
IL (1) IL159840A0 (en)
MA (1) MA26128A1 (en)
MX (1) MXPA04000675A (en)
NO (1) NO20040294L (en)
NZ (1) NZ530703A (en)
PL (1) PL373392A1 (en)
RU (1) RU2321406C9 (en)
SK (1) SK442004A3 (en)
UA (1) UA76997C2 (en)
WO (1) WO2003011262A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (en) * 2001-07-23 2003-02-06 Bayer Ag Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
JP2006219374A (en) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Imidazotriazinone derivative having pde 7 inhibition
DE102004023069A1 (en) 2004-05-11 2005-12-08 Bayer Healthcare Ag New dosage forms of the PDE 5 inhibitor vardenafil
DE102004038328A1 (en) * 2004-08-06 2006-03-16 Bayer Healthcare Ag New uses of 2-phenyl-substituted imidazotriazinone derivatives
CN101163476A (en) 2005-04-19 2008-04-16 尼科梅德有限责任公司 Roflumilast for the treatment of pulmonary hypertension
US8648073B2 (en) 2009-12-30 2014-02-11 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
AT512084A1 (en) * 2011-10-20 2013-05-15 Univ Wien Tech DIAZABICYCLO AND DIAZASPIRO ALKAN DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
JP7150721B2 (en) * 2016-12-16 2022-10-11 システィック・ファイブロシス・ファンデーション Bicyclic Heteroaryl Derivatives as CFTR Enhancers
CN113461694A (en) * 2021-08-05 2021-10-01 广东西捷药业有限公司 Vardenafil analogue and synthetic method and application thereof
CN113583003A (en) * 2021-08-05 2021-11-02 广东西捷药业有限公司 Vardenafil analogue and synthetic method and application thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791025A (en) 1971-11-19 1973-05-07 Allen & Hanburys Ltd HETEROCYCLIC COMPOUNDS
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DK109578A (en) 1977-03-25 1978-09-26 Allen & Hanburys Ltd PROCEDURE FOR MAKING HETEROCYCLIC COMPOUNDS
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4479210A (en) * 1982-11-19 1984-10-23 U.S. Philips Corporation Record-disc player
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
ATE219765T1 (en) * 1995-04-10 2002-07-15 Fujisawa Pharmaceutical Co INDOLE DERIVATIVES AS CGMP-PDE INHIBITORS
EP0882718B1 (en) * 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
DE19812462A1 (en) * 1998-03-23 1999-09-30 Bayer Ag New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
CN100436418C (en) * 1997-12-12 2008-11-26 Osi制药公司 N-Benzyl-3-indenylacetamides derivatives for treating neoplasia
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19827640A1 (en) 1998-06-20 1999-12-23 Bayer Ag New imidazotriazine derivatives useful as smooth muscle relaxants for treating e.g. cardiovascular disorders, cerebrovascular disorders, or erectile dysfunction
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
FR2792634B1 (en) * 1999-04-20 2001-06-01 Synthelabo 2-ALCOXY-CYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
IL130968A (en) * 1999-07-15 2002-12-01 Shmuel Simon Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
AU775102B2 (en) * 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology
DE19943815A1 (en) * 1999-09-14 2001-03-15 Merck Patent Gmbh Use of thienopyrimidines
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
ATE341329T1 (en) * 1999-10-12 2006-10-15 Lilly Icos Llc MEDICINAL PRODUCTS FOR THE TREATMENT OF NEUROPATHIES
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical compositions for treatment of neuropathy comprising an inhibitor of cyclic guanosine 3',5'-monophosphate phosphodiesterase 5 and either gabapentin or pregabalin
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
JP2004500425A (en) * 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー Use of cyclic GMP-specific phosphodiesterase inhibitors for the treatment of Parkinson's disease
AU2001257146B2 (en) * 2000-04-19 2006-11-30 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
KR20030023747A (en) * 2000-08-11 2003-03-19 화이자 인코포레이티드 Treatment of the insulin resistance syndrome
CA2419623A1 (en) * 2000-08-30 2002-03-07 Lilly Icos Llc Method for treatment of migraine using pde5 inhibitors
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
AU2002226633A1 (en) * 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
DE10107639A1 (en) 2001-02-15 2002-08-22 Bayer Ag 2-alkoxyphenyl substituted imidazotriazinones
EP1392314B1 (en) * 2001-05-09 2006-12-20 Bayer HealthCare AG NOVEL USE OF 2-[2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on
DE10135815A1 (en) * 2001-07-23 2003-02-06 Bayer Ag Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
JP2005527510A (en) * 2002-03-06 2005-09-15 セレジー ファーマシューティカルズ インコーポレーティッド Formulations and methods for using nitric oxide mimetics in the treatment of cancer

Similar Documents

Publication Publication Date Title
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
AU2003279338A1 (en) Phenethanolamine derivatives for the treatment of respiratory diseases
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
SI1487828T1 (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2002333510A1 (en) Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
AU2003270683A1 (en) Compounds for the treatment of premature ejaculation
AU2002359635A1 (en) Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
AU2002365621A1 (en) Composition for treating the surface of the skin
GB0201025D0 (en) The treatment of degenerative diseases
AU2003269257A1 (en) Use of cap-1 for the therapy of asthma
AU2003236787A1 (en) Use of alkylphosphocholines for the preventative treatment of protozoan diseases
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2002344959A1 (en) Use of fasl for the treatment of neurodegenerative diseases